Compare ZVRA & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZVRA | NAVI |
|---|---|---|
| Founded | 2006 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 689.4M | 760.4M |
| IPO Year | 2015 | 2014 |
| Metric | ZVRA | NAVI |
|---|---|---|
| Price | $9.81 | $8.47 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 7 |
| Target Price | ★ $25.00 | $9.00 |
| AVG Volume (30 Days) | 744.9K | ★ 1.1M |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 7.22% |
| EPS Growth | ★ 159.21 | N/A |
| EPS | ★ 0.74 | 0.44 |
| Revenue | $106,470,000.00 | ★ $271,000,000.00 |
| Revenue This Year | $43.97 | $56.36 |
| Revenue Next Year | $15.93 | $6.64 |
| P/E Ratio | ★ $14.00 | $20.13 |
| Revenue Growth | ★ 350.91 | N/A |
| 52 Week Low | $8.01 | $7.33 |
| 52 Week High | $15.04 | $13.48 |
| Indicator | ZVRA | NAVI |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 36.98 |
| Support Level | $9.29 | $7.91 |
| Resistance Level | $11.19 | $8.73 |
| Average True Range (ATR) | 0.46 | 0.34 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 3.61 | 12.23 |
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in two segments: Federal Education Loans, and Consumer Lending. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.